Expert Practice Guidelines for Autosomal Dominant Polycystic Kidney Disease
Expert Practice Guidelines for Autosomal Dominant Polycystic Kidney Disease
- ADPKD is a Mendelian autosomal dominant disorder where at-risk individuals have a 50% chance of inheriting the disease.Pre-symptomatic diagnosis of at-risk adults is most commonly performed by ultrasound due to its low cost and availability.1
- The Ravine Pei Unified Criteria is used for diagnosis and exclusion.2,3
- Genetic testing in ADPKD is seldom indicated for diagnosis but is useful for disease exclusion in at-risk persons age 40 and
younger. Other considerations for genetic testing include PKD with no apparent family history, evaluation as a living-related
organ donor, markedly asymmetric PKD, early and severe presentation or PKD with syndromic features and reproductive
counseling.4,5
Monitoring Disease Progression
- Kidney enlargement resulting from the expansion of cysts is continuous and quantifiable, and is associated with the decline of renal function.6
- Total Kidney Volume (TKV) is the most important prognostic biomarker for following ADPKD progression in the early stages of the disease. It is used to predict end-stage renal disease and implement appropriate treatment strategies in a timely fashion.7,8
- TKV can be obtained from a variety of modalities but is most precise with MRI and CT scan. The Mayo Clinic Imaging Classification uses height-adjusted TKV and age to categorize typical ADPKD patients from 1A to 1E with those in classes 1C, 1D and 1E being considered rapid progressors.6,9
Management
- Tolvaptan is FDA-approved (April 2018) to slow kidney function decline in adults at risk of rapidly progressing ADPKD.10
- A Risk Evaluation Mitigation Strategy (REMS) exists for acute liver failure so continuous monitoring of liver function is recommended.11
- Patients with ADPKD are at increased risk for hypertension, cardiovascular events and cardiovascular mortality. According to the HALT-PKD trials, blood pressure goals are <110/75 mmHg for early PKD (age 60, as long as patients are asymptomatic for hypotension) and 120-130/70-80 mmHg for advanced PKD (GFR <60).12
- Nutritional and lifestyle recommendations to mitigate renal/extrarenal manifestations and slow disease progression include moderate protein intake, low sodium intake, high water intake, low-to-moderate caffeine intake, no smoking and achieving a healthy weight and BMI.13-17
1. Chebib FT, Torres VE, Am J Kidney Dis. 2016 May;67(5): 792–810. 2. Ravine D, et al. Lancet 1994 Apr;343(8901):824-827. 3. Pei Y, et al. JASN 2009 Jan;20(1):205-212. 4. Lanktree MB, et al. Nephrol Dial Transplant. 2019 Sept;34(9):1453–1460. 5. Lanktree MB, et al. CJASN 2020;16:790-799. 6. Grantham JJ, et al. N Engl J Med 2006;354:2122-2130. 7. Chapman AB, et al. Clin J Am Soc Nephrol. 2012 Mar;7(3):479–486. 8. Irazabal MV, Rangel LJ, Bergstralh EJ, et al. J Am Soc Nephrol. 2015;26(1):160-172. 9. https://www.mayo.edu/research/documents/pkd-center-adpkd-classification/doc-20094754 10. https://pkdcure.org/tolvaptan 11. Torres VE, Chapman AB, et al. CJASN 2021;16(1)48-58. 12. Schrier RW, et al. N Engl J Med 2014;371:2255-66. 13. Torres VE, et al. Kidney Int 2017;91:493-500. 14. Higashihara E, et al. Nephrol Dial Transplant 2014;29:1710-1719. 15. McKenzie KA, et al. BMC Nephrol 2018;19:378. 16. Orth SR, et al. Kidney Int 1998;54:926-931. 17. Nowak KL, et al. J Am Soc Nephrol 2018;29:571-578. 18. Chapman AB, et al. N Engl J Med 1992;327:916-920.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Expert Practice Guidelines for Autosomal Dominant Polycystic Kidney Disease
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended

Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective

IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
HF Management for Patients with Comorbid Conditions
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?